View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔1/30/2019 3:51:34 PM 1044

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 December 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) New CEO Appointed to Accelerate Global Growth

🕔1/23/2019 9:48:46 AM 1802

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Leo Lee as the company's new Chief Executive Officer and member of Board of Directors, effective immediately. Leo will succeed the outgoing CEO, John Martin, after 10 years of valuable service to the company.

Read Full Article

Regeneus Ltd (ASX:RGS) Chinese Patent Granted for Biomarkers for Stem Cell Therapy

🕔12/3/2018 9:34:26 AM 2403

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the State Intellectual Property Office of China has granted the Company a patent for the use of biomarkers to monitor disease progression in a patient having mesenchymal cell therapy for inflammatory conditions.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders

🕔11/22/2018 2:06:22 PM 2691

Regeneus Ltd (ASX:RGS) provides the Company's Chairman Address to Shareholders.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation for AusBiotech 2018

🕔10/31/2018 4:26:22 PM 2203

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results for the Period Ended 30 September 2018

🕔10/24/2018 9:08:53 AM 2031

Regeneus Ltd (ASX:RGS) provides the Company's quarterly results for the period ended 30 September 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) European Patent Office Issues Notice of Intention to Grant European Patent

🕔10/18/2018 9:11:57 AM 2137

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce it has received a Notice of Intention to Grant a European patent covering the use of Progenza by the European Patent Office.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.4M

🕔9/6/2018 9:18:09 AM 3347

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.4m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) FY18 Results and Business Update

🕔8/30/2018 2:32:07 PM 2816

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to provide an overview of its results for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Annual Report 2018

🕔8/30/2018 2:13:22 PM 2750

Your Directors present their report for Regeneus Ltd (ASX:RGS) and its controlled entities for the financial year ended 30 June 2018.

Read Full Article
###

105,053 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 242) (Last 30 Days: 1814) (Since Published: 48371) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media